What We're Reading: Page 114
Industry reads hand-picked by our editors
Jan 12, 2023
Jan 11, 2023
-
Bloomberg
Seagen’s New CEO David Epstein Hunts for Cancer Deals
-
C&EN
Agilent will double oligonucleotide capacity
-
CNN
FDA vaccine advisers ‘disappointed’ and ‘angry’ that early data about new Covid-19 booster shot wasn’t presented for review last year
-
MIT Technology Review
The scientist dreaming of a factory of unlimited human organs
Jan 10, 2023
Jan 09, 2023
-
Bloomberg
Billionaires for a ‘Hot Minute’: Biotech Slump Whipsaws Boston Founders
-
Stat News
Day One drug shrinks tumors in common pediatric brain cancer
-
The Wall Street Journal
71-Year-Old Cancer Patient Broke Trial Age Limits for a Chance at a Cure
-
Evaluate Vantage
Valrox shows signs of plateauing
Jan 06, 2023
-
The Financial Times
A pharma partnership that brought a breakthrough in breast cancer
-
Evaluate Vantage
The biggest-selling drugs of 2023
-
The Wall Street Journal
New Biden Law Won’t Kill Drug Cures. It Will Reshape Them.
-
Bloomberg
The US Keeps Offering China Its Covid Vaccines. China Keeps Saying No
Jan 05, 2023
Jan 04, 2023
-
Evaluate Vantage
After 33 years Geron could have an approved drug
-
The Wall Street Journal
Healthcare Deal-Making Set to Surge in 2023
-
Science
Revised clinical trial form for Alzheimer’s antibody warned of fatal brain bleeds
-
Associated Press
FDA finalizes rule expanding availability of abortion pills
Previous
